Literature DB >> 10752939

Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro.

A Solomon1, R Shmilowich, D Shasha, J Frucht-Pery, J Pe'er, S Bonini, F Levi-Schaffer.   

Abstract

PURPOSE: To examine the effect of human conjunctival fibroblasts on the survival and functional activity of human peripheral blood eosinophils.
METHODS: Eosinophils were purified by negative immunoselection [magnetic activated cell sorter (MACS), purity > 97%] from volunteers with mild atopia. Fibroblasts were cultured from conjunctival specimens of healthy donors. Eosinophils were cultured on confluent monolayers of conjunctival fibroblasts or in culture medium alone. Eosinophil survival was evaluated by the trypan blue exclusion test. Eosinophil adherence was assessed by counting the attached cells after washing the cultures. Eosinophil viability and adherence in coculture were also assessed in the presence of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-interleukin (IL)-3, and anti-IL-5 neutralizing antibodies. Cocultured eosinophils were activated by lipopolysaccharide (LPS) after 4 days in culture, and eosinophil peroxidase (EPO) release was determined as a marker of their activation.
RESULTS: Eosinophils cocultured with conjunctival fibroblasts had a significantly increased viability of 35.9% (P = 0.004) and 12.8% (P = 0.003) on days 4 and 8, respectively. Fibroblast-conditioned medium did not enhance the survival of eosinophils. The increase in eosinophil survival in coculture was partially inhibited by anti-GM-CSF (P = 0.019), anti-IL-3 (P = 0.033), or anti-IL-5 (P = 0.011), whereas eosinophil adherence was reduced by anti-GM-CSF alone (P = 0.034). LPS activation of eosinophils cultured for 4 days with conjunctival fibroblasts induced higher EPO release than in freshly isolated eosinophils (P = 0.01).
CONCLUSIONS: Human conjunctival fibroblasts induced prolonged survival and increased secretory function of human peripheral blood eosinophils. Increased survival is partially mediated by IL-3, IL-5, and GM-CSF. The coculture of conjunctival fibroblasts with eosinophils can serve as an in vitro system for the study of eosinophil behavior in the ocular surface and of cellular interactions in allergic eye diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752939

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Cyclical orbital eosinophilic myositis.

Authors:  Mahiul M K Muqit; Robert H Taylor
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

2.  Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.

Authors:  Simone Wendlinger; Jonas Wohlfarth; Sophia Kreft; Claudia Siedel; Teresa Kilian; Ulrich Dischinger; Markus V Heppt; Kilian Wistuba-Hamprecht; Friedegund Meier; Matthias Goebeler; Dirk Schadendorf; Anja Gesierich; Corinna Kosnopfel; Bastian Schilling
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

3.  Blood Eosinophils Subtypes and Their Survivability in Asthma Patients.

Authors:  Andrius Januskevicius; Egle Jurkeviciute; Ieva Janulaityte; Virginija Kalinauskaite-Zukauske; Skaidrius Miliauskas; Kestutis Malakauskas
Journal:  Cells       Date:  2020-05-18       Impact factor: 6.600

4.  The Enhanced Adhesion of Eosinophils Is Associated with Their Prolonged Viability and Pro-Proliferative Effect in Asthma.

Authors:  Andrius Januskevicius; Ieva Janulaityte; Virginija Kalinauskaite-Zukauske; Reinoud Gosens; Kestutis Malakauskas
Journal:  J Clin Med       Date:  2019-08-22       Impact factor: 4.241

5.  An open microfluidic coculture model of fibroblasts and eosinophils to investigate mechanisms of airway inflammation.

Authors:  Yuting Zeng; Xiaojing Su; Meg G Takezawa; Paul S Fichtinger; Ulri N Lee; Jeffery W Pippin; Stuart J Shankland; Fang Yun Lim; Loren C Denlinger; Nizar N Jarjour; Sameer K Mathur; Nathan Sandbo; Erwin Berthier; Stephane Esnault; Ksenija Bernau; Ashleigh B Theberge
Journal:  Front Bioeng Biotechnol       Date:  2022-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.